SMYD3 and lung adenocarcinoma: Since they target different substrates, it is unlikely that these two distinct enzymes would compensate for each other, but the dual inactivation of SMYD2 and SMYD3 may inhibit PDAC (and lung adenocarcinoma) more potently than the inactivation of each enzyme alone.